Orthopedics

Your Article Summary

See Latest Articles

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
Annals of Rheumatic Diseases, 09/08/09

Dore RK et al. – Denosumab increases BMD and reduces bone turnover in patients with RA and may provide a new therapeutic option for reducing systemic bone loss in patients with RA.

• Randomized, double-blind, placebo-controlled, phase II study of denosumab, an investigational RANKL inhibitor, in patients with RA concurrently receiving treatment with bisphosphonates or glucocorticoids
• Patients received subcutaneous placebo (n=75), denosumab (60 mg; n=71), or denosumab (180 mg; n=72) at baseline and 6 months

• Denosumab treatment increased mean lumbar spine and hip BMD and reduced sCTx-I and P1NP versus placebo through 12 months, regardless of baseline BMD or marker levels or concomitant bisphosphonate or glucocorticoid use

Related Articles

See all related articles

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The Journal of Urology, 11/16/09    Relevance Score: 87%

A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09    Relevance Score: 83%

Bone health and prostate cancer
Prostate Cancer & Prostatic Diseases, 11/13/09    Relevance Score: 77%

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

A perspective on male osteoporosis
Best Practice & Research: Clinical Rheumatology, 12/03/09

Vitamin K2 supplementation does not influence bone loss in early menopausal women: A randomised double-blind placebo-controlled trial
Osteoporosis International, 12/03/09

Quantifying the material and structural determinants of bone strength
Best Practice & Research: Clinical Rheumatology, 12/03/09

 See all of Bone Metabolism